Search Results 131-140 of 23161 for B cell lymphomas

  1. About CAR-T cell therapy - Mayo Clinic

    Aggressive B-cell lymphoma not otherwise specified (NOS); Mantle cell lymphoma; Follicular lymphoma; Multiple myeloma. People who have relapsed or refractory ...

  2. T-cell lymphoma - Doctors and departments - Mayo Clinic

    N. Nora Bennani, M.D.. Internist; Oncologist; Hematologist. Rochester, MN. Areas of focus: CAR-T cell therapy, B- ...

  3. Lymphoma - Doctors and departments - Mayo Clinic

    Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...

  4. Transplant Medicine Physicians - Medical Professionals - Mayo Clinic

    ... B-cell lymphoma, Acute myelogenous leukemia, Non-Hodgkin lymphoma, Burkitt lymphoma, T-cell lymphoma, Follicular lymphoma, Hodgkin lymphoma ...

  5. Lymphoma - Doctors and departments - Mayo Clinic

    Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...

  6. A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma - Mayo Clinic

    A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Overview · Participation ...

  7. Lymphoma - Doctors and departments - Mayo Clinic

    Bone marrow transplant, Chronic lymphocytic leukemia, B-cell lymphoma, Lymphoma, Small lymphocytic lymphoma, Follicular... lymphoma, Brain lymphoma. Show ...

  8. Lymphoma - Doctors and departments - Mayo Clinic

    Developing the first genetic test to help guide the diagnosis and treatment of people with diffuse large B-cell lymphoma, the most common type of non-Hodgkin ...

  9. Publications - Grzegorz S. Nowakowski, M.D. - Mayo Clinic

    Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin. Cancer Epidemiol Biomarkers Prev ...

  10. A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma - Mayo Clinic

    CD20+Diffuse Large B-Cell Lymphoma. · Ann Arbor stage 3 or 4 or stage 2 with bulky disease · High or high-intermediate disease risk. · No prior anti-lymphoma ...